Besides vemurafenib and other BRAF inhibitors, which have been in clinical use for many years, the selective ERK1/2 inhibitor SCH772984, has been tested in vivo in xenograft melanoma models [22], and other ERK inhibitors, such as Ulixertinib and MK-8353, have already been tested in phase 1 clinical trials [43,44]. Here, BRAF is linked to melanoma.